Variations in Comorbidities Among Patients with Diastolic Heart Failure (DHF) Based on Outcomes and Gender Differences

Main Article Content

Muhammad Sarim Khan, Rimsha Habib, Saman Javed, Hassan Raza

Keywords

Diastolic Heart Failure, Comorbidities, Gender Differences, Patient Outcomes, Retrospective Cohort Study, Hypertension, Chronic Kidney Disease, Atrial Fibrillation.

Abstract

Background: Diastolic Heart Failure (DHF) with reduced or normal EF and reduced diastolic function of the left ventricle is that more common and is likely to affect the elderly. It is nonetheless quite challenging to diagnose and manage DHF in particular owing to the fact that most patients have other serious health conditions; these vary along gender lines and affect the mortality and hospitalization rates for the patients. It is important to know these variations to be able to devise effective and specific ways for handling stroke patients with DHF. 

Abstract 44 | PDF Downloads 5

References

[1] S. Campbell-Quintero, "Comorbidity profile and outcomes in patients with chronic heart failure
in a Latin American country: Insights from the Colombian heart failure registry (RECOLFACA),"
International Journal of Cardiology, vol. 378, pp. 123-129, 2023.
[2] J. E. Halabi, "Differential impact of systolic and diastolic heart failure on in-hospital treatment,
outcomes, and cost of patients admitted for pneumonia," American Journal of Medicine Open,
vol. 9, p. 100025, 2023.
[3] J. A. Lorido, "Comorbidity in patients with type 2 diabetes mellitus and heart failure with
preserved ejection fraction. Cluster analysis of the RICA registry. Opportunities for
improvement," Revista Clínica Española (English Edition), vol. 220, no. 7, pp. 409-416, 2020.
[4] N. S. Schafauser, "Influence of heart failure (HF) comorbidity in chronic obstructive pulmonary
disease (COPD) and isolated forms of HF and COPD on cardiovascular function during
hospitalization," Respiratory Medicine, vol. 231, p. 107731, 2024.
[5] A. Mazza, "The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced
ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world
settings," Biomedicine & Pharmacotherapy, vol. 130, p. 110596, 2020.